Abstract Number: 1590 • ACR Convergence 2025
Association of levels of soluble CD13 with clinical features and fibrosis in systemic sclerosis patients
Background/Purpose: Soluble CD13 (sCD13), released by the cleavage of cell surface CD13 by matrix metalloproteinase-14 (MMP14), has potent proinflammatory, angiogenic, and arthritogenic activities. The receptors…Abstract Number: 0972 • ACR Convergence 2025
Prominent endothelial senescence in systemic sclerosis skin
Background/Purpose: Systemic sclerosis (SSc) is characterized by extensive damage of the microvessels in multiple organs. We and others showed that endothelial cells (ECs) isolated from…Abstract Number: 0685 • ACR Convergence 2025
Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention
Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to…Abstract Number: 2471 • ACR Convergence 2025
Automated Feedback and Quality Control in Nailfold Capillaroscopy: A Tool for Clinical and Educational Use
Background/Purpose: Nailfold capillaroscopy is a key tool in the early diagnosis of systemic sclerosis and related disorders. However, incorrect image acquisition can lead to misclassification…Abstract Number: 1589 • ACR Convergence 2025
Nintedanib in Systemic Sclerosis-Associated Interstitial Lung disease: Real-World Cohort Study on Tolerability and Discontinuation
Background/Purpose: Nintedanib slows the progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, potential high discontinuation rates due to adverse side-effects raise concerns about its…Abstract Number: 0971 • ACR Convergence 2025
Unraveling the role of the hippo pathway in systemic sclerosis: A focus on TEADs and VGLL3
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by excessive collagen production, leading to the thickening and hardening of skin and internal organs.…Abstract Number: 0682 • ACR Convergence 2025
Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study
Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges…Abstract Number: 2165 • ACR Convergence 2025
Targeted Needs Assessment of Provider Medical Knowledge of Juvenile Scleroderma, a Mixed Methods Study
Background/Purpose: Juvenile scleroderma (JS) is an autoimmune disease that can cause skin sclerosis leading to deformity, disability, and early mortality especially with delayed diagnosis. A…Abstract Number: 1582 • ACR Convergence 2025
Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Background/Purpose: There have not been large US-based studies of digital pitting scars (DPS) and digital ischemic ulcers (DIU) in systemic sclerosis. Utilizing the Collaborative National…Abstract Number: 0965 • ACR Convergence 2025
Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is characterized by progressive fibrosis driven by sustained fibroblast activation and senescence. Nicotinamide N-methyltransferase (NNMT), a SAM-dependent enzyme, is upregulated in…Abstract Number: 0681 • ACR Convergence 2025
Evaluation of Serial Cardiovascular Magnetic Resonance Monitoring and Immunosuppressive Therapy in Predicting Long-Term Outcomes in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease that can manifest as widespread skin and visceral fibrosis, potentially affecting major organs including the heart.…Abstract Number: 0692 • ACR Convergence 2024
Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis
Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is one of the leading causes of morbidity and mortality. Recently,…Abstract Number: 0957 • ACR Convergence 2024
Increased Collagen Deposition and Altered Immune Cell Profiles Are Present in Early and Late Stage Systemic Sclerosis with Gastrointestinal Involvement
Background/Purpose: Gastrointestinal tract (GIT) involvement is highly prevalent among patients with systemic sclerosis (SSc) and is associated with high morbidity and mortality. However, treatment options…Abstract Number: 1571 • ACR Convergence 2024
Growth Differentiation Factor 15 Is a Serum Biomarker and Pathogenic Factor of Progressive Fibrosis in Systemic Sclerosis
Background/Purpose: In systemic sclerosis (SSc), interstitial lung disease (ILD) remains the leading cause of mortality. A decline in forced vital capacity (FVC) is considered a…Abstract Number: 1824 • ACR Convergence 2024
Skin Macrophage Subtypes and Impact of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis: Results from Single-cell Analyses of an Observational Data Set and a Phase I/II Randomized Controlled Trial
Background/Purpose: Macrophages play a major role in dcSSc-related skin fibrosis, with a mixed M1-M2 activation profile relying on the activation of JAK/STAT. Tofacitinib, a pan-JAK…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 33
- Next Page »
